Date: 2011-03-09
Type of information: R&D agreement
Compound: orally available small molecule therapies that trigger or support beta cell replication.
Company: Evotec (Germany) Harvard University (USA) Howard Hughes Medical Institute (USA)
Therapeutic area: Metabolic diseases
Type agreement: R&D
Action mechanism:
Disease: Diabetes
Details: Evotec has established a research collaboration with Harvard University and the Howard Hughes Medical Institute (HHMI) aimed at discovering and developing new treatments in the field of diabetes. The initial goal of the collaboration is to pursue a comprehensive and systematic approach towards the identification and development of physiological mechanisms and targets that regulate beta cell replication. Further details and commercial terms of the cooperation are not disclosed.
Financial terms:
Latest news:
